Egalet's OXAYDO Receives Pharmaceutical Composition Patent Protection Until 2024

Egalet (NASDAQ:EGLT), which develops specialty pharmaceuticals for pain management and other conditions, today announces a new patent has been issued for OXAYDO. This product was originally licensed from Acura Pharmacueticals.
According to the press release:

The United States Patent and Trademark Office (USPTO) issued patent 9,492,443 broadly covering immediate-release pharmaceutical compositions comprising an opioid formulated with Acura Pharmaceutical’s proprietary Aversion^® Technology intended to discourage common routes of abuse, including snorting. The patent offers protection through 2024.

Egalet’s CEO, Bob Rade, said the following:

“Issuance of this patent further highlights the uniqueness of the OXAYDO formulation, the only approved immediate-release oxycodone designed to discourage abuse via one of the most common routes of oxycodone abuse—snorting.”

Read the full press release here.